Biora Therapeutics, Inc.
BIORQ
$0.1174
-$0.0086-6.83%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 4,855.56% | 777.55% | 172.00% | -98.69% | -97.52% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4,855.56% | 777.55% | 172.00% | -98.69% | -97.52% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 4,855.56% | 777.55% | 172.00% | -98.69% | -97.52% |
| SG&A Expenses | -7.29% | 11.87% | 15.39% | -1.91% | -9.54% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.62% | 18.18% | 17.43% | 8.15% | -1.88% |
| Operating Income | 9.92% | -16.90% | -16.89% | -8.68% | 0.86% |
| Income Before Tax | 70.69% | -37.60% | -112.88% | -152.64% | -2.49% |
| Income Tax Expenses | -159.85% | -126.84% | 90.00% | 78.57% | 133.08% |
| Earnings from Continuing Operations | 70.88% | -36.51% | -114.52% | -154.63% | -3.41% |
| Earnings from Discontinued Operations | 1,694.86% | -97.70% | -97.81% | -97.95% | -130.15% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 74.24% | -60.10% | -165.29% | -225.27% | -4.36% |
| EBIT | 9.92% | -16.90% | -16.89% | -8.68% | 0.86% |
| EBITDA | 9.79% | -17.46% | -17.48% | -9.37% | 0.09% |
| EPS Basic | 88.66% | -1.65% | -52.63% | -72.74% | 44.56% |
| Normalized Basic EPS | 83.96% | 69.08% | 37.45% | 16.43% | 66.99% |
| EPS Diluted | 86.41% | -5.54% | -52.60% | -72.72% | 44.53% |
| Normalized Diluted EPS | 82.31% | 67.60% | 37.45% | 16.43% | 66.99% |
| Average Basic Shares Outstanding | 171.80% | 169.25% | 137.83% | 106.18% | 61.29% |
| Average Diluted Shares Outstanding | 254.61% | 268.11% | 137.83% | 106.18% | 61.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
